BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance

PURPOSE: BluePrint (BP) is an 80-gene molecular subtyping test that classifies early-stage breast cancer (EBC) into Basal, Luminal, and HER2 subtypes. In most cases, breast tumors have one dominant subtype, representative of a single activated pathway. However, some tumors show a statistically equal...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuilman, Midas M., Ellappalayam, Architha, Barcaru, Andrei, Haan, Josien C., Bhaskaran, Rajith, Wehkamp, Diederik, Menicucci, Andrea R., Audeh, William M., Mittempergher, Lorenza, Glas, Annuska M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464757/
https://www.ncbi.nlm.nih.gov/pubmed/35984580
http://dx.doi.org/10.1007/s10549-022-06698-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464757/
https://www.ncbi.nlm.nih.gov/pubmed/35984580
http://dx.doi.org/10.1007/s10549-022-06698-x

Ejemplares similares